
RealRate

PHARMACEUTICAL 2021

NUGENEREX IMMUNO-ONCOLOGY INC.

Rank 336 of 409



RealRate

PHARMACEUTICAL 2021

NUGENEREX IMMUNO-ONCOLOGY INC.

Rank 336 of 409

The relative strengths and weaknesses of NUGENEREX IMMUNO-ONCOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NUGENEREX IMMUNO-ONCOLOGY INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,709% points. The greatest weakness of NUGENEREX IMMUNO-ONCOLOGY INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 189% points.

The company's Economic Capital Ratio, given in the ranking table, is -441%, being 86% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,841
Liabilities, Non-Current	0
Other Assets	0.084
Other Compr. Net Income	0
Other Expenses	855
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	397
Revenues	0
Selling, General and Administrative Expense	336

Output Variable	Value in 1000 USD
Assets	0.084
Liabilities	5,841
Expenses	1,589
Stockholders Equity	-5,841
Net Income	-1,589
Comprehensive Net Income	-1,589
Economic Capital Ratio	-441%